Accession Number:

ADA512882

Title:

Harnessing Functional Genomics to Reverse Chemoresistance in Breast Cancer

Descriptive Note:

Annual summary rept. 14 Sep 2007-14 Sep 2008

Corporate Author:

TEXAS UNIV AT DALLAS SOUTHWESTERN MEDICAL CENTER

Personal Author(s):

Report Date:

2008-10-01

Pagination or Media Count:

20.0

Abstract:

Targeted therapy has proven to be an effective strategy in the treatment of breast cancer. An example of successful targeted therapy is trastuzumab, a humanized monoclonal antibody binds to the extracellular domain of HER2, a receptor which is overexpressed in many breast cancers. The goal of my project is to identify molecular targets for conjunctive therapy that will increase efficacy of trastuzumab therapy. To identify molecular targets necessary for breast cancer cell survival in the presence of trastuzumab, a breast cancer cell line with known cytostatic sensitivity to trastuzumab, will be screened using a high throughput assay using a with a unique small interfering siRNA library targeting all 21,125 known genes in the human genome database. This information will help identify new synergistic combinations with existing drugs and novel therapeutic targets that can act synergistically as initial therapy and upon the development of resistance. During the time covered by this annual summary, I have uncovered an important signaling nexus regulating cell survival and drug resistance in breast cancer cells.

Subject Categories:

  • Biochemistry
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE